Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals
Medical Oncology · 2025
DOI: 10.1007/s12032-025-03090-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2025. Verfasst von Ali Nakhaei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, MMS.C., Islamic Azad University, Mashhad, Iran. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Transforming Growth Factor beta, Phytochemicals. Die Arbeit nennt 160 Literaturangaben.
Abstract (Originalsprache)
Glioblastoma (GBM), the most aggressive type of primary brain tumor in adults, is characterized by a poor prognosis and considerable resistance to current therapies. Traditional treatment approaches-surgery, radiation, and chemotherapy-offer few clinical benefits and are often linked to increased recurrence rates and significant adverse effects. This underscores the urgent need for novel therapeutic strategies. Targeting the transforming growth factor-beta (TGF-β) signaling pathway is a viable strategy. TGF-β acts as a tumor suppressor during the first stages of cancer but promotes tumor progression, angiogenesis, immune evasion, and the creation of an immunosuppressive tumor microenvironment in GBM. The deregulation of TGF-β signaling has been shown to interact with essential carcinogenic pathways, including the Wnt/β-catenin, PI3K/AKT, and Notch pathways, therefore aggravating GBM pathogenesis. TGF-β plays a pivotal role in controlling glioma stem cells and influencing the permeability of the blood-brain barrier, making it an attractive target for therapeutic intervention. Novel treatment approaches, including small-molecule inhibitors and monoclonal antibodies, as well as the use of phytochemicals such as flavonoids, quercetin, and other phytochemicals targeting specific elements of the TGF-β signaling pathway, have shown encouraging results in preclinical investigations and early-stage clinical trials. These novel strategies may enhance clinical outcomes and mitigate treatment limitations in GBM therapy by leveraging this system's combined tumor-suppressive and immune-regulatory properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, MMS.C., Islamic Azad University, Mashhad, Iran.
- Student Research Committee, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
- Student Research Committee, Faculty of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Basic Sciences, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
- Department of Basic Sciences, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran. Amirreza.afshari2@gmail.com.
Zitieren
APA
Nakhaei, A., Abedi, M., Afshari, S., Mohtashami, A., Jalili-Nik, M., Jalali, M., & Afshari, A. R. (2025). Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals. Medical Oncology. https://doi.org/10.1007/s12032-025-03090-9
Vancouver
Nakhaei A, Abedi M, Afshari S, Mohtashami A, Jalili-Nik M, Jalali M, et al. Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals. Medical Oncology. 2025. doi:10.1007/s12032-025-03090-9
BibTeX
@article{Nakhaei2025,
author = {Nakhaei, Ali and Abedi, Mehdi and Afshari, Sadaf and Mohtashami, Alireza and Jalili-Nik, Mohammad and Jalali, Mahsa and Afshari, Amir R},
title = {Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals},
journal = {Medical Oncology},
year = {2025},
doi = {10.1007/s12032-025-03090-9}
}
EUVIMED